These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 26051430)

  • 1. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.
    Siddiqui SH; Guasconi A; Vestbo J; Jones P; Agusti A; Paggiaro P; Wedzicha JA; Singh D
    Am J Respir Crit Care Med; 2015 Aug; 192(4):523-5. PubMed ID: 26051430
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
    Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
    Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations.
    Singh D; Kampschulte J; Wedzicha JA; Jones PW; Cohuet G; Corradi M; Higenbottam T; Petruzzelli S; Vestbo J
    Eur Respir J; 2013 Jan; 41(1):12-7. PubMed ID: 22653766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.
    Mantero M; Radovanovic D; Santus P; Blasi F
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2319-2333. PubMed ID: 30104872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
    De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status.
    Brusselle G; Peché R; Van den Brande P; Verhulst A; Hollanders W; Bruhwyler J
    Respir Med; 2012 Jun; 106(6):811-9. PubMed ID: 22357130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
    Quinn D; Seale JP; Reisner C; Fischer T; Golden M; Fernandez C; Darken P; St Rose E; Thomas M; Tardie G; Orevillo C
    Respir Med; 2014 Sep; 108(9):1327-35. PubMed ID: 25060541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
    Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
    Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
    Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
    Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.
    Wedzicha JA; Singh D; Vestbo J; Paggiaro PL; Jones PW; Bonnet-Gonod F; Cohuet G; Corradi M; Vezzoli S; Petruzzelli S; Agusti A;
    Respir Med; 2014 Aug; 108(8):1153-62. PubMed ID: 24953015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/formoterol.
    Vos W; De Backer J; Poli G; De Volder A; Ghys L; Van Holsbeke C; Vinchurkar S; De Backer L; De Backer W
    Respiration; 2013; 86(5):393-401. PubMed ID: 23595105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood eosinophil levels as a biomarker in COPD.
    Brusselle G; Pavord ID; Landis S; Pascoe S; Lettis S; Morjaria N; Barnes N; Hilton E
    Respir Med; 2018 May; 138():21-31. PubMed ID: 29724389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma.
    Maspero J; Cherrez I; Doherty DE; Tashkin DP; Kuna P; Kuo WL; Gates D; Nolte H; Chylack LT
    Respir Med; 2014 Sep; 108(9):1355-62. PubMed ID: 25044280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease.
    John M; Bosse S; Oltmanns U; Schumacher A; Witt C
    Respir Med; 2005 Nov; 99(11):1418-24. PubMed ID: 15894479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tregs and HLA-DR expression in sputum cells of COPD patients treated with tiotropium and formoterol.
    Holownia A; Wielgat P; Stasiak-Barmuta A; Kwolek A; Jakubow P; Szepiel P; Chyczewska E; Braszko JJ; Mroz RM
    Adv Exp Med Biol; 2015; 839():7-12. PubMed ID: 25315616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung.
    Razzetti R; Bergamaschi M; Villetti G; Bolzoni P; Civelli M; Berti F; Rossoni G
    Pharmacol Res; 2007 May; 55(5):426-32. PubMed ID: 17336541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
    Wang J; Nie B; Xiong W; Xu Y
    J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled corticosteroids increase siglec-5/14 expression in sputum cells of COPD patients.
    Wielgat P; Mroz RM; Stasiak-Barmuta A; Szepiel P; Chyczewska E; Braszko JJ; Holownia A
    Adv Exp Med Biol; 2015; 839():1-5. PubMed ID: 25252903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.